Axillary Lymph Node Dissection Rates and Prognosis From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer

In conclusion, although survival did not differ significantly, more NCT patients might able to avoid ALND, with fewer LNs removed with lower LN positivity.Clinical Trial Registrationhttps://clinicaltrials.gov/ct2/show/NCT01622361, identifier NCT01622361.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

AbstractIntroductionThe interaction between breast cancer and migraine is complex and not fully elucidated. Large epidemiological studies point towards a beneficial effect of migraines on breast cancer (BC). We aimed to investigate the BC –migraine relationship, with strict data checks and clinical evaluations of both BC and common headache forms.MethodsConsecutive BC patients were evaluated with the International Classification of Headache Disorders. Clinical data on the BC subtypes and treatments were collected. Parametric and nonparametric statistics were used according to data distributions.ResultsFifty patients ...
Source: Neurological Sciences - Category: Neurology Source Type: research
ConclusionReproductive risk factors are associated with SD BC, as are HR+ tumors. Differences in BC-risk factor associations according to detection method may be related to prevailing phenotypes among categories.
Source: Cancer Causes and Control - Category: Cancer & Oncology Source Type: research
Conclusions. Clinical use of the DiviTum®TKa assay is expected to decrease traditional imaging and monitoring and may reduce the overall cost of managing mBC if it leads to clinical decisions to avoid futile therapy. Post-coverage, real world monitoring of palliative therapies among post-menopausal mBC populations is needed to better categorize cost savings over time.PMID:34763605 | DOI:10.1080/13696998.2021.2003674
Source: Journal of Medical Economics - Category: Health Management Authors: Source Type: research
J Oncol. 2021 Oct 8;2021:9657071. doi: 10.1155/2021/9657071. eCollection 2021.ABSTRACTBreast cancer is a heterogeneous disease in which genetic factors are involved in disease worsening and higher mortality. Epidemiological and clinical research revealed that breast cancer incidence continues to rise. 100 histopathologically confirmed untreated newly diagnosed cases of invasive ductal carcinoma (IDC) of breast and 100 healthy subjects were involved and blood samples were collected in non-EDTA plain vials. Serum was separated by centrifugation, total RNA was extracted from serum, and cDNA synthesis was done to study the miR...
Source: Journal of Oncology - Category: Cancer & Oncology Authors: Source Type: research
Basel, 17 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced interim data from the randomised phase II coopERA Breast Cancer trial evaluating neoadjuvant treatment with giredestrant (formerly known as GDC-9545), an investigational next generation oral selective oestrogen receptor degrader (SERD), in post-menopausal women with ER-positive, HER2-negative early breast cancer. In the window of opportunity phase, after 14 days of treatment, giredestrant showed a reduction in Ki67, a prognostic marker that measures tumour proliferation, compared to anastrozole (80% versus 67% respectively, p=0.0222). The safety ...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
Conclusions: radiomic features extracted from tumor edema contribute significantly to predicting tumor histology, increasing the accuracy obtained from the combination of patient clinical characteristics and breast imaging data.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
ConclusionPatients with ER-low/HER2 − breast cancer had similar clinicopathological characteristics, treatments, and outcomes as patients with TNBC irrespective of disease setting. Further research is needed to understand predictive and prognostic factors associated with ER-low/HER2− disease.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
AbstractMale breast cancer (MBC) is rare, accounting for less than 1% of all breast cancer but the incidence has increased worldwide. Risk factors include increased longevity, obesity, testicular diseases and tumours, and germline mutations of BRCA2. BRCA2 carriers have 80 times the risk of the general population. Men generally present with breast cancer at an older age compared with women. Histologically, MBC is often of grade 2, hormone receptor positive, HER2 negative, and no special type carcinoma although in situ and invasive papillary carcinomas are common. Reporting and staging are similar to female breast cancer. M...
Source: Virchows Archiv - Category: Pathology Source Type: research
ObjectiveTo investigate whether radiomics features extracted from multi-parametric MRI combining machine learning approach can predict molecular subtype and androgen receptor (AR) expression of breast cancer in a non-invasive way.Materials and MethodsPatients diagnosed with clinical T2–4 stage breast cancer from March 2016 to July 2020 were retrospectively enrolled. The molecular subtypes and AR expression in pre-treatment biopsy specimens were assessed. A total of 4,198 radiomics features were extracted from the pre-biopsy multi-parametric MRI (including dynamic contrast-enhancement T1-weighted images, fat-suppresse...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
AbstractBackgroundMenstrual and parity history might impact the risk for breast cancer. Data on the impact of these factors on other tumor characteristics are limited.MethodsA single center retrospective cohort study comprising all women with estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative, early breast cancer whose tumors were sent to OncotypeDX analysis. The prespecified subgroups were investigated: age of menarche (
Source: Hormones and Cancer - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Docetaxel | Endocrine Therapy | HER2 | Mastectomy | Men | Menopause | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Study | Tamoxifen | Taxotere | Women